Novo Nordisk puts AI at the centre of its clinical strategy

- Novo Nordisk is quietly rewriting the rules of the GLP-1 game, not just with molecules, but with algorithms. Ibrahim Kamstrup-Akkaoui reveals a strategy where AI isn’t a buzzword, but the bedrock of their clinical foundation. Imagine trials designed by machine learning, predicting patient responses before the first pill is swallowed. It’s med-tech with an odd charm: data-driven empathy. No sensationalism here, just the steady hum of servers optimizing human health. As we say in the lab, this biopsy has a ticker symbol. The future of obesity treatment isn’t just chemical; it’s computational. Crypto Express 3000 approves this digital-infrastructure pivot.